KR20240149941A - 간 질환 치료를 위한 TRβ 작용제 VK2809의 경구 제형 및 그 제조 방법 - Google Patents

간 질환 치료를 위한 TRβ 작용제 VK2809의 경구 제형 및 그 제조 방법 Download PDF

Info

Publication number
KR20240149941A
KR20240149941A KR1020247030354A KR20247030354A KR20240149941A KR 20240149941 A KR20240149941 A KR 20240149941A KR 1020247030354 A KR1020247030354 A KR 1020247030354A KR 20247030354 A KR20247030354 A KR 20247030354A KR 20240149941 A KR20240149941 A KR 20240149941A
Authority
KR
South Korea
Prior art keywords
dosage form
oral dosage
compound
form according
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247030354A
Other languages
English (en)
Korean (ko)
Inventor
브라이언 리안
제프리 이. 바커
모린 반스
윌리엄 호예
Original Assignee
바이킹 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이킹 테라퓨틱스 인코포레이티드 filed Critical 바이킹 테라퓨틱스 인코포레이티드
Publication of KR20240149941A publication Critical patent/KR20240149941A/ko
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/665Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247030354A 2022-02-18 2023-02-13 간 질환 치료를 위한 TRβ 작용제 VK2809의 경구 제형 및 그 제조 방법 Pending KR20240149941A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263311905P 2022-02-18 2022-02-18
US63/311,905 2022-02-18
US202263312650P 2022-02-22 2022-02-22
US63/312,650 2022-02-22
PCT/US2023/012935 WO2023158616A1 (en) 2022-02-18 2023-02-13 ORAL DOSAGE FORMS OF TRβ AGONIST VK2809 FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME

Publications (1)

Publication Number Publication Date
KR20240149941A true KR20240149941A (ko) 2024-10-15

Family

ID=87578867

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247030354A Pending KR20240149941A (ko) 2022-02-18 2023-02-13 간 질환 치료를 위한 TRβ 작용제 VK2809의 경구 제형 및 그 제조 방법

Country Status (9)

Country Link
US (1) US20250134913A1 (https=)
EP (1) EP4479062A4 (https=)
JP (1) JP2025505802A (https=)
KR (1) KR20240149941A (https=)
CN (1) CN119072316A (https=)
AU (1) AU2023220955A1 (https=)
CA (1) CA3251549A1 (https=)
MX (1) MX2024010009A (https=)
WO (1) WO2023158616A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
CN118615254A (zh) * 2023-03-08 2024-09-10 甘莱制药有限公司 片剂及其制备方法与用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL372247A1 (en) * 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
WO2007109605A2 (en) * 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
CN116942684A (zh) * 2020-02-20 2023-10-27 甘莱制药有限公司 一种用于治疗脂肪性肝炎的药物组合物及其制备方法
US11752161B2 (en) * 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof
JP7470204B2 (ja) * 2020-03-27 2024-04-17 ガンネックス ファーマ カンパニー リミテッド 医薬組成物、その調製方法及び使用方法
TW202315608A (zh) * 2021-07-06 2023-04-16 中國大陸商甘萊製藥有限公司 用於治療肝臟疾病的聯合治療

Also Published As

Publication number Publication date
EP4479062A4 (en) 2026-03-04
JP2025505802A (ja) 2025-02-28
MX2024010009A (es) 2024-08-22
US20250134913A1 (en) 2025-05-01
CA3251549A1 (en) 2023-08-24
EP4479062A1 (en) 2024-12-25
CN119072316A (zh) 2024-12-03
AU2023220955A1 (en) 2024-08-15
WO2023158616A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
KR20240149941A (ko) 간 질환 치료를 위한 TRβ 작용제 VK2809의 경구 제형 및 그 제조 방법
US20220202779A1 (en) Oral preparation of glucokinase activator and preparation method therefor
US11786470B2 (en) Solid pharmaceutical compositions and processes for their production
ES2596291T3 (es) Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
RS66566B1 (sr) Farmaceutska kombinacija i kompozicija, i kombinovani preparat koji sadrži aktivator glukokinaze i biguanid hipoglikemijski lek kao i postupak njihove pripreme i upotrebe
US20210228489A1 (en) Compositions for treating cystic fibrosis
KR102841419B1 (ko) sGC 자극제를 포함하는 고체 분산물
KR20110116027A (ko) 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 의약 포뮬레이션
CN106456662A (zh) 口服给药的戊聚糖多硫酸盐的组合物及其使用方法
KR102197465B1 (ko) 디메틸푸마르산염을 함유한 장용성 정제
BR112013030456B1 (pt) Composição farmacêutica compreendendo pozitinib e lubrificante de sal não metálico, método para preparar uma formulação da dita composição e método para estabilizar a dita composição
JP2013529637A (ja) 5−エチル−2−{4−[4−(4−テトラゾル−1−イル−フェノキシメチル)−チアゾール−2−イル]−ピペリジン−1−イル}−ピリミジンの組成物
TW202315608A (zh) 用於治療肝臟疾病的聯合治療
CN120322236A (zh) 用于治疗肝脏疾病的口服剂型及其制备方法
CN114126712A (zh) 无定形司巴森坦(sparsentan)组合物
RU2769863C1 (ru) Твердая лекарственная форма аватромбопага и способ ее получения
WO2022051319A1 (en) Fixed dose combinations of chs-131 and a dpp-4 inhibitor
WO2022051318A1 (en) Fixed dose combinations of chs-131 and a thyroid receptor beta agonist
WO2025218797A1 (zh) 一种胶囊或固体制剂及其应用
WO2025218795A1 (zh) 一种药物组合物及其应用
TR2022002231A2 (tr) Di̇meti̇l fumarat i̇çeren enteri̇k kapli mi̇ni̇ tabletleri̇ i̇çeren kapsül ve bunun hazirlanmasina yöneli̇k yöntem
TR201605929A1 (tr) Di̇yabeti̇n tedavi̇si̇ i̇çi̇n terapöti̇k formülasyonlar

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000